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Duchenne muscular dystrophy (DMD) is a
hereditary disease caused by mutations that
disrupt the dystrophin mRNA reading frame. In
some cases, forced exclusion (skipping) of a sin-
gle exon can restore the reading frame, giving
rise to a shorter, but still functional, protein. In
this study, we constructed lentiviral vectors
expressing antisense oligonucleotides in order
to induce an efficient exon skipping and to
correct the initial frameshift caused by the
DMD deletion of CD133+ stem cells. The intra-
muscular and intra-arterial delivery of geneti-
cally corrected CD133 expressing myogenic
progenitors isolated from the blood and muscle
of DMD patients results in a significant recov-
ery of muscle morphology, function, and dys-
trophin expression in scid/mdx mice. These
data demonstrate that autologous engrafting
of blood or muscle-derived CD133+ cells,
previously genetically modified to reexpress
a functional dystrophin, represents a promising
approach for DMD.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is characterized by
a lack of dystrophin protein at the sarcolemma of muscle
fibers (Hoffman et al., 1987; Watkins et al., 1988), a condi-
tion that results clinically in progressive muscle weakness
associated with chronic degeneration and regeneration
of skeletal myofibers. The lack of dystrophin expression
arises from mutations that disrupt the production of
a translatable transcript from the dystrophin gene, most
commonly by deletions or duplications that cause a shift646 Cell Stem Cell 1, 646–657, December 2007 ª2007 Elsevierin its open reading frame. Currently there is no therapy
to prevent DMD or to halt its progression. One suggested
route to therapy proposes the use of viral or nonviral vec-
tors to deliver the full-length dystrophin or one of a number
of versions of mini-dystrophin gene that have been dem-
onstrated to assuage the muscle weakness commonly
observed in mdx dystrophic mice (Acsadi et al., 1996;
Hartigan-O’Connor and Chamberlain, 2000; Scott et al.,
2002; Lai et al., 2005; Li et al., 2006). In this context, trans-
gene expression persisted and prevented subsequent
muscle fiber degeneration for at least 6 months (Dickson
et al., 2002; Roberts et al., 2002). Transplantation of nor-
mal myogenic cells into dystrophin-deficient muscle is
an alternative therapeutic approach, and it has been dem-
onstrated that transplanted myogenic cells contribute to
muscle regeneration giving rise to skeletal muscle fibers
expressing functional dystrophin protein (Partridge et al.,
1989; Huard et al., 1992, 1994; Tremblay et al., 1993;
Beauchamp et al., 1999; Vilquin et al., 1995; Gussoni
et al., 1997, 1999; Smythe and Grounds, 2001; Skuk
et al., 2006). However, myoblast transplantation has sev-
eral limitations, including immune rejection, poor cellular
survival rates, and limited dissemination of the injected
cells (Huard et al., 1992, 1994; Tremblay et al., 1993;
Vilquin et al., 1995; Gussoni et al., 1997; Beauchamp
et al., 1999; Smythe and Grounds, 2001; Skuk et al., 2006).
Thus, alternative stem or progenitor cells with myogenic
capacity are being investigated (Gussoni et al., 1999; Lee
et al., 2000; Blau et al., 2001; Goodell et al., 2001; Seale
et al., 2001; Jackson et al., 2002; Qu-Petersen et al.,
2002; Dreyfus et al., 2004; Dezawa et al., 2005; Goncalves
et al., 2006). Among these adult stem cells, we previously
showed that human blood-derived progenitors, express-
ing the CD133 surface marker, are able to regenerate dys-
trophic muscle fibers (Torrente et al., 2004). Here, we have
extended these observations to a combination of cell- and
gene-based approaches via the ex vivo introduction of
corrective genes into dystrophic CD133+ myogenic cells,Inc.
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Dystrophin Restoration by Exon-Skipped Stem CellsFigure 1. Characterization of Muscle
CD133+ Cells
FACscan immunophenotyping of the fraction-
ated normal (A) and dystrophic (B) muscle-
derived CD133+ cells. Less than 5% of the
normal muscle-derived CD133+ cells coex-
pressed the CD34 antigen, whereas 53% of
them coexpressed CXCR4 (A). Otherwise,
more than 79% of the CD133+ cells isolated
from dystrophic muscle coexpressed CD34
and CXCR4 antigens (56%, [B]). Twenty-
one days after i.m. transplantation of normal
(C) and DMD (D) muscle CD133+ cells, several
human spectrin-positive myofibers were seen
in the TA of the scid/mdx mice. Examination
of vascular structures of injected dystrophic
muscles disclosed human injected lamin A/C
(red in [E] and [G]) coexpressing the VE-cad-
herin (green in [F]) endothelial marker (arrows
in [E]–[G]) near vascular structures stained
with laminin (magenta in [E], [F], and [G]). Merg-
ing of (E) and (F) is shown in (G). After injection
into dystrophic muscle, several human nuclear
lamin A/C-positive cells (red in [H]) were dis-
tributed near the capillary network (arrows) of
host myofibers, coexpressing a-SMA antigen
(green in [I]). (L) shows the merging of (H) and
(I). Nuclei were stained blue with Dapi.which would permit their subsequent autologous trans-
plantation. Use of the patient’s own cells would reduce
the risk of implant rejection.
As a correction method, we used the exon-skipping
approach. This technology uses specific antisense oligo-
nucleotides (AONs) designed to mask the putative splicing
sites of exons in the mutated region of the primary RNA
transcript whose removal would reestablish a correct
reading frame. The majority of DMD mutations are local-
ized into the central rod domain of the dystrophin where
in-frame removal of central spectrin-like repeats, as in
mini- or microdystrophin constructs, has been demon-
strated to conserve functionality (Gregorevic and Cham-
berlain, 2003); for this reason, this protein is well suited
to exon-skipping strategies.
In fact, there is a clinical trial currently underway to test
the efficacy, safety, and tolerability of a single intramuscu-
lar dose of AONs to restore production of the dystrophin
in DMD patients (Leiden Muscular Dystrophy page,
www.dmd.nl).
Moreover, in vivo exon-skipping has previously been
achieved in the mdx model through a gene therapy ap-
proach using an AAV vector to introduce and to spread
the production of specific AONs through dystrophic mus-
cles (Goyenvalle et al., 2004; Denti et al., 2006). These re-
sults demonstrate the efficiency of this method to recover
the expression of a shorter but functional dystrophin that
is able to recruit its associated proteins (i.e., sarcoglycans
and dystroglycans).
We have thus sought to combine cell therapy using
human dystrophic blood and muscle-derived stem cells
sharing the CD133 antigen and gene therapy based on
exon skipping correction to deliver a functional dystrophinCell Sinto the scid/mdx dystrophic mice. Both stem cell popula-
tions were transduced with a lentiviral vector expressing
the U7 snRNA containing antisense sequences designed
specifically to skip exon 51 and able to restore open read-
ing frame to a range of DMD genotypes. In accordance
with our hypothesis, the genetically engineered DMD
stem cells expressed a shortened dystrophin mRNA
specifically deleted for the exon 51. Moreover, genetically
engineered DMD stem cells restore the dystrophin synthe-
sis and contribute to the regeneration of dystrophic skele-
tal muscles. These data demonstrate that genetically
engineered blood or muscle-derived CD133+ cells repre-
sent a possible tool for future stem cell based autografts
applications in DMD.
RESULTS
Characterization of CD133+ Cells Derived
from the Normal and DMD Muscles
Our previous results demonstrated the capacity of human
blood CD133+ cells to participate in regeneration of dys-
trophic muscle (Torrente et al., 2004). Here, we first inves-
tigated whether CD133+ human progenitors are present
into skeletal muscle tissue and whether they exhibit myo-
genic properties. Cells were isolated from human normal
and dystrophic muscles and characterized by flow cytom-
etry (Figure 1). CD133+ cells isolated from normal muscle
represent 1% of the total mononucleated muscle cells
with no interindividual differences between the specimens
(14–70 years) (Figure 1A). Less than 5% of the normal
muscle derived CD133+ cells coexpressed the CD34
antigen, whereas 53% of them coexpressed CXCR4
(Figure 1A). On the other hand, dystrophic muscletem Cell 1, 646–657, December 2007 ª2007 Elsevier Inc. 647
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Dystrophin Restoration by Exon-Skipped Stem CellsFigure 2. Myogenic and Endothelial Potentialities of Muscle CD133+ Cells
Colonies from single cells within the CD133+ subpopulation isolated from the muscle (A) were obtained in proliferative conditions. The progeny of
these single CD133+ cells differentiate into a-SMA+ cells ([B] and [D] in green) and into myogenic cells, as demonstrated by specific RT-PCR (H)
for human myogenic markers from normal (lane 1) and DMD muscle CD133+ cells (lane 2) and C2C12 murine cell lane (lane ) and human cDNA
library (lane +), and confirmed by immunostaining for MyHC ([C] and [D] in red) expression. (I) Immunoblotting analysis confirmed the myogenic ex-
pression of slow myosin heavy chain (MyHC) and M-cadherin in muscle CD133+ cells (lane MDSC). 3T3 fibroblast and G8 myoblast cell lines were
used as control (lanes 3T3 and G8, respectively). Utrophin immunoblotting indicated that the same total protein concentration was present in all spec-
imens. A tube formation assay was also used to determine the capability of conditioned muscle CD133+ cells media to regulate the angiogenesis (E
and F). Capillary formation was observed when the human endothelial cells (HUVEC) were cultured with supernatant of normal (E) and dystrophic (F)
muscle CD133+ cells. Induction of CD31+ capillaries in HUVEC cell cultures was quantified (G) comparing the effect of a VEGF-conditioned medium
(lane VEGF, positive control) and the muscle CD133+ cell-conditioned medium (lane MDSC supernatant).CD133+ cells represent a range from 0.1%–5% of the to-
tal nucleated cells isolated from dystrophic muscle with
significant interindividual differences between the speci-
mens, according to the degree of muscle degeneration
(5–17 years) (Figure 1B). More than 79% of CD133+ cells
derived from dystrophic expressed CD34, whereas56%
of these cells were CXCR4 positive (Figure 1B). Less than
4% of the CD133+ cells isolated from either normal or
dystrophic muscles were found to express the pan-
leukocyte common antigen CD45 (data not shown). The
CD133+ cells isolated from normal and dystrophic mus-
cles proliferate well and can be expanded in vitro. Some
of single CD133+ cells replicated, giving rise to adherent
clonal colonies (Figure 2A). The majority of these clones
appear phenotypically identical and homogeneous for
marker expression. Detection by RT-PCR revealed tran-
scripts of human Pax-7, Myf-5, MyoD, M-cadherin,
MRF-4, and Myogenin, in both normal and dystrophic
CD133+ populations after 24 hr of culture, suggesting
a certain degree of myogenic commitment (Figure 2H) in
comparison with blood-derived CD133+ cells that are
negative for these markers (Torrente et al., 2004). After
14 days in ‘‘fusion-promoting,’’ low-serum conditions,648 Cell Stem Cell 1, 646–657, December 2007 ª2007 Elsevieboth normal and dystrophic muscle-derived CD133+ cells
fused into multinucleated myosin+ myotubes that ex-
pressed muscle specific gene products as revealed by
immunoblot analysis (Figure 2I). Although all clones differ-
entiated into myotubes, they appeared heterogeneous
with variability between myotubes as to the amounts of
a-smooth muscle actin (a-SMA) expressed (Figures 2B
and 2D).
We also investigated whether human normal and
dystrophic muscle progenitors can exhibit myogenic
properties in vivo after implantation into the muscle of
the immunodeficient scid/mdx mice. Two months after
intramuscular (i.m.) transplantation of muscle CD133+
cells, we found human spectrin+ myofibers coexpressing
the human lamin A/C and with no differences between
muscles injected with normal (215 ± 91 +ve myofibers
per section) and dystrophic (193 ± 74 +ve myofibers per
section) sources (Figures 1C and 1D). Moreover, several
donor cells contained human lamin A/C+ nuclei and
coexpressed markers of endothelial cells, CD31 and
VE-cadherin (Figures 1E–1G), near and within small ves-
sels in the injected area (normal and dystrophic CD133+
generated, respectively, 21% and 19% of the totalr Inc.
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Dystrophin Restoration by Exon-Skipped Stem CellsFigure 3. Exon Skipping of DMD Cells Transduced by Lentivirus Vectors
(A) Top: schematic map of the U7exon51 lentiviral vector. The two long terminal repeats (LTR) enclose the encapsidation signal (J), the Rev-respon-
sive element (RRE), the central polypurine tract (cPPT), the woodchuck hepatitis virus responsive element (WPRE), and the U7exon51 transgene in-
versely inserted. Middle: the U7exon51 cassette is constituted of the U7SmOPT sequence placed under the control of its natural U7 promoter and 30
downstream elements. Bottom: sequence of the U7SmOPT cassette with the human exon 51 antisense oligoribonucleotide sequences (h51AON 1
and 2) placed upstream the Sm protein linking site and the 30 U7 helix-loop structure.
(B) Schematic representation of the D49-50 DMD deletion, which creates a codon dephasing between the exons 48 and 51 (black circle), and the
expected link generated by skipping exon 51.
(C) Evaluation of the exon skipping in nontransduced and transduced D49-50 DMD blood (lanes 1 and 3, respectively)- and muscle (lanes 2 and 4,
respectively)-derived CD133+ cells was performed by nested PCR (SM, size markers). Muscle and blood blanks (lanes 5 and 6, respectively) were
used as controls.
(D) Sequencing of the skipped band confirms splicing of exons 48 to 52 after U7exon51 transduction.
(E) Schematic map showing the five major human dystrophin isoforms and the human specific primers used to distinguish the isoforms.
(F) PCR results from blood- and muscle-derived CD133+ cells after 7 days of culture in proliferation (stem-cell-conditioned) and differentiation
(myogenic-conditioned) medium. Lanes 1 to 5 correspond to the expression of the different dystrophin isoforms indicated in (E). Lane 6 corresponds
to the amplification of the b-actin gene as a standard. Only in myogenic conditions the human transduced DMD blood- and muscle-derived CD133+
cells express the full length dystrophin isoform mRNA.lamin A/C+ cells per cross-section). Lamin A/C+ cells ex-
pressing the a-SMA marker were also observed around
muscle capillaries, suggesting a pericyte commitment
(Figures 1H–1L). Moreover, the supernatant of muscle
CD133+ cells induced the formation of CD31+ capillaries
in vitro from human endothelial cells (Figures 2E–2G).
Together, these data suggest that CD133+ cells derived
from normal or dystrophic muscle have been recruited
into muscle fibers and muscle vessels, indicating a myo-
endothelial progenitor status.
U7 Exon 51 Lentivirus Vector Induces an Efficient
Exon Skipping in Blood- and Muscle-Derived
CD133+ DMD Cells In Vitro
As a possible treatment for dystrophic muscles, we inves-
tigated the combination of exon skipping and cell-based
therapy. Blood- and muscle-derived CD133+ cells,
obtained from a DMD patient exhibiting a frameshifting
deletion of exons 49 and 50 of the dystrophin gene de-
letion (D49-50), were transduced by lentivirus vectorsCell Sharbouring a cassette designed to favor skipping of
exon 51 from the dystrophin mRNA (Figure 3A). Such
targeted skipping should generate an in-frame dystrophin
mRNA sequence from the D49-50 DMD mutation
(Figure 3B). The antisense sequences targeting potential
human exon 51 were selected from several exon-internal
AONs on the basis of their capacity to promote the exon
skipping in over 25% of transcripts of myoblasts as previ-
ously described (Van Deutekom and van Ommen, 2003;
Aartsma-Rus et al., 2005). We used a vector incorporating
the selected two sequences (23 and 20 nucleotides)
located across two enhancers of splicing elements (ESE)
situated in exon 51 of the DMD gene. To test whether
this would induce skipping of exon 51 in vitro, CD133+
cells isolated from the blood and muscle of dystrophic
D49-50 DMD patients were transduced with the U7 exon
51 lentivirus vector. Total mRNA was collected and ana-
lyzed by nested RT-PCR. In proliferation conditions, trans-
duced dystrophic blood-derived CD133+ cells express
only the 71 kDa mRNA of the ubiquitously expressedtem Cell 1, 646–657, December 2007 ª2007 Elsevier Inc. 649
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Dystrophin Restoration by Exon-Skipped Stem Cellsdystrophin isoform (Figure 3F). In these same culture
conditions, however, transduced CD133+ cells derived
from dystrophic muscle express the 71 kDa, 116 kDa,
and 140 kDa dystrophin mRNA isoforms (Figure 3F). To
test whether myogenesis promotes expression of the
full-length dystrophin isoform by the skipping of the
exon 51, transduced dystrophic blood-derived CD133+
cells were cocultured with murine myoblasts (ratio 1/50),
whereas muscle-derived CD133+ cells were cultured in
low-serum conditions. After 14 days of culture in these
myogenic conditions, both dystrophic CD133+ cell popu-
lations generated the full-length dystrophin isoform mRNA
and efficient exon-skipping as revealed by RT-PCR anal-
ysis (Figure 3C) and DNA sequencing (Figure 3D).
Genetically Engineered Blood- or Muscle-Derived
CD133+ Dystrophic Cells Participate in Skeletal
Muscle Regeneration of Dystrophic Mice after
In Vivo Transplantation
In these experiments, we investigated whether genetically
engineered dystrophic human CD133+ progenitors iso-
lated from blood or muscle can exhibit in vivo myogenic
properties after implantation into the muscle of adult
mouse recipients. 2 3 104 dystrophic CD133+ cells iso-
lated from the blood and muscle were transduced with
the U7 exon 51 lentivirus vector and injected 24 hr later
into the right TA muscle of 24 scid/mdx mice. Twenty-
one and 45 days postinjection, the transplanted muscles
were harvested and characterized by immunohistochem-
istry. We counted the donor human lamin A/C-positive
cells in all the serial sections of injected TA muscles.
Forty-five days after transplantation, muscles of animals
injected with blood-derived, transduced CD133+ cells
contained numerous mononucleated human lamin A/C-
positive cells in the interstitial spaces, 4.5 + 0.7% of which
coexpressed the CD31 and 5.6 + 1.2% of which coex-
pressed VE-cadherin, markers of endothelial cells (data
not shown). Transplantation of muscle-derived trans-
duced CD133+ cells produced similar results: 5 + 1.2%
of the total human lamin A/C positive cells coexpressed
endothelial markers (data not shown). To investigate
whether blood- and muscle-skipped CD133+ cells could
enter the satellite cell niche beneath the basal lamina of
host fibers 45 days after transplantation, we stained for
M-cadherin, laminin, and human lamin A/C. Of the human
lamin A/C-positive donor cells, 7 ± 2.2% of those derived
from CD133+ blood cells and 9 ± 1.4% of those derived
from CD133+ muscle cells expressed M-cadherin in the
injected muscles. These cells were located beneath the
basal lamina closely juxtaposed against skeletal muscle fi-
bers and accounted for 1.5% of the total sublaminal nuclei
per muscle section (Figures 4D–4F). These results strongly
suggest that intramuscularly transplanted skipped blood
and muscle-derived CD133-positive cells are competent
to give rise to interstitial endothelial cells and to satellite
cells. To confirm the in vivo ability of CD133-positive cells
isolated from the blood to differentiate into human muscle
fibers, RT-PCR for human M-cadherin, Myf-5, analysis
of Myogenin, Pax7, MyoD, and MRF4 mRNAs was650 Cell Stem Cell 1, 646–657, December 2007 ª2007 Elsevierperformed on muscles from scid/mdx mice, which had
been injected intramuscularly. M-cadherin and Pax7 are
known to be expressed in both quiescent satellite cells
and myoblasts in adult muscle (Seale et al., 2000). Human
M-cadherin, Myf-5, and Pax7 were detected in all injected
TA muscles, suggesting that blood- and muscle-derived
CD133 stem cells differentiate in vivo into satellite cells
(Figure 4C) together with human-specific MyoD and
MRF4 mRNAs (data not shown), suggesting the differenti-
ation of the transduced cells into mature myofibers. No
human transcripts were detected in the muscles of control
noninjected scid/mdx. Twenty-one days after i.m. trans-
plantation of transduced blood- and muscle-derived
CD133+ cells, the number of human dystrophin positive
myofibers was, respectively, 60.1 ± 32.3 (n = 6) and 90.3 ±
33.5 (n = 6) per muscle maximal cross-section area
(Table 1). By 45 days, the mean number of human dystro-
phin positive myofibers per muscle maximal cross-section
area had increased to 136.1 ± 53.5 (n = 6) and 416.6 ±
52.8 (n = 6), respectively, suggesting a continuing recruit-
ment of donor cells to the regenerating dystrophic muscle
(Figure 4). Moreover, 21 days after i.m. transplantation of
transduced blood- and muscle-derived CD133+ cells,
the average number of human lamin A/C-positive cells/
section (51 ± 7 [n = 5] and 86 ± 3 [n = 5], respectively)
was significantly (p < 0.001) reduced by 45 days (9 ±
[n = 50] and 11 ± 4 [n = 5], respectively), suggesting that
mononuclear cells had been recruited into muscle fibers.
In all injected muscles, many of the human dystrophin-
positive fibers expressed the human lamin A/C (data not
shown). The clusters of dys+ fibers in muscles injected
with blood- and muscle-derived transduced CD133+
stem cells were also positive for a-sarcoglycans and
b-sarcoglycans (Figure 5). Thus, the reexpression of an
in-frame human dystrophin is sufficient to assemble the
dystrophin-associated protein complex (Figure 5). To con-
firm the reestablishment of a truncated but functional
human dystrophin in positive fibers, we extracted total
mRNA and performed nested RT-PCR to verify the
effect of the skipping of the DMD dystrophin mRNA. We
found a conspicuous exon 51-skipped transcript in mus-
cles injected with transduced blood- or muscle-derived
CD133+ cells (Figure 4A), confirming that the clusters of
positive fibers mainly represented the consequence of
exon-51 skipped human dystrophin mRNA. CD133 cells
isolated from the blood and muscle dystrophic tissues and
transduced with the U7 exon 51 lentivirus were also trans-
planted into the TA of 6 scid/mdx mice. The samples from
the muscles injected with the blood CD133-negative frac-
tion did not show any skipping. In contrast, the muscles in-
jected with the transduced muscle-derived CD133 cells
showed a faint skipped band (Figure 4A), which probably
derived from skipping of the dystrophin mRNA originating
from the donor CD133myoblasts. In addition, we verified
skipping of exon 51 in vivo by sequence analysis show-
ing the linkage between exons 48 and 52 (Figure 4B).
Together, these results demonstrate that lentivirally trans-
duced CD133+ cells issuing either from DMD blood or
skeletal muscle participate in regeneration of dystrophicInc.
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Dystrophin Restoration by Exon-Skipped Stem CellsFigure 4. In Vivo Exon Skipping Analysis
and Muscle Localization of Transplanted
Human Mononucleated Stem Cells
(A) Efficiency of exon skipping in intramuscu-
larly injected scid/mdx muscles. Nested PCR
analyses revealed efficient skipping in TA mus-
cles injected with transduced D49-50 DMD
blood- and muscle-derived CD133+ cells
(lanes 1 and 3, respectively) and at a low level
in muscle injected with transduced muscle-de-
rived CD133 cells (lane 4). No skipped bands
were seen in nontransduced D49-50 DMD
blood-derived CD133+ cells (lane 5) and in
transduced D49-50 DMD blood-derived
CD133 cells (lane 2). The endogenous dys-
trophin from untransplanted scid/mdx TA mus-
cle is shown in lane 6 (lane 7, blank; SM, size
marker; *endogenous dystrophin; **nonskipped
human dystrophin; ***skipped human dystro-
phin). (B) DNA sequencing confirms the effi-
ciency of the exon skipping by the link between
the exons 48 and 52. (C) RT-PCR was per-
formed to analyze the expression of some
myogenic markers. Scid/mdxmuscles injected
with transduced D49-50 DMD blood-derived
CD133+ cells (lane 1) show the expression of
three markers of satellite cells, the human
M-cadherin (m-cad), myf-5,and pax-7;a human
endothelial marker, CD31, is also expressed
in these samples. Similar results are seen in
muscles injected with transduced D49-50 DMD
muscle-derived CD133+ cells (lane 2). Muscles
issued from the injection of transduced D49-50
DMD muscle-derived CD133 cells (lane 4)
show the expression of M-cadherin, whereas
no myogenic or endothelial markers were ob-
served in muscles injected with transduced D49-50 DMD blood-derived CD133 cells; normal human muscle cDNA was used as positive control
(lane +) and normal C57BL6 mouse cDNA as negative control (lane); human specific b-actin primers were used as a standard. (D) Immunohistochem-
istry on a scid/mdx muscle injected intramuscularly with transduced D49-50 muscle-derived CD133+ stem cells. Double-staining antibodies against
human lamin nuclear A/C (green in [D] and [F]) and M-Cadherin (red in [E] and [F]) show that some donor cells express markers typical of satellite cells
both outside and beneath (arrows) the basal lamina (identified by laminin staining in magenta). These cells appear pink in the merged image (F) of (D) and
(E). Nuclei were stained blue with Dapi. Colocalization of human dystrophin (green) and DAPI (blue) demonstrates the formation of human myofibers in
dystrophic muscles from the genetically engineered human DMD blood (G)- and muscle (H)-derived CD133+ cells 21 days after their intramuscular
transplantation. Forty-five days after intramuscular transplantation, we found increased numbers of human dystrophin-positive myofibers in muscles
that had received blood (I)- and muscle (L)-derived CD133+ cells. The muscles of scid/mdx animals (M) showed a considerable decrease in necrosis and
central nucleated myofibers 45 days after intramuscular transplantation of genetically engineered human DMD blood (N)- and muscle (O)-derived
CD133+.muscle fibers after intramuscular injection and that the
transduced plasmid efficiently skips exon 51 of the human
dystrophin gene. The possibility that injected CD133-pos-
itive cells may revert, at least in part, to the dystrophic
phenotype was examined by morphometric analysis of
hematoxylin and eosin-stained muscle sections from
i.m. injected and noninjected scid/mdx. Untreated scid/
mdx muscles showed classic signs of muscular dystro-
phy, including hypertrophic fibers, small regenerating
fibers, necrosis, centrally located nuclei, and occasional
fibrosis (Torrente et al., 2004). Muscles of scid/mdx ani-
mals injected with transduced blood- and muscle-derived
CD133+ cells showed a marked decrease in these dystro-
phic characteristics (Figures 4L–4O). The cross-sectional
area of myofibers generated by CD133+ cells derived from
blood (1655 ± 163; n = 5) and muscle (1781 ± 99; n = 5)
was significantly larger (p < 0.001, Student’s t test) thanCell Sthat of untreated scid/mdx muscles (1243 ± 122; n = 5).
Moreover, the coefficient of variance in myofiber diame-
ter was smaller (206 ± 13) within the injected muscle
area than within uninjected scid/mdx muscles examined
(512 ± 34) (p < 0.001, Student’s t test). Another indicator
of ongoing regeneration in muscular dystrophy is the
increase in the percentage of myofibers with centrally lo-
cated nuclei. High frequencies of centrally located nuclei
(25%) were observed in all scid/mdx muscles examined,
and these levels were reduced in injected muscles
(around 17%).
Intra-Arterial Delivery of Genetically Engineered
Muscle CD133+ Dystrophic Cells Is Followed
by Functional Recovery of Dystrophic Mice
To determine whether transduced DMD muscle-derived
CD133+ cells are also capable of engraftment andtem Cell 1, 646–657, December 2007 ª2007 Elsevier Inc. 651
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Dystrophin Restoration by Exon-Skipped Stem CellsTable 1. D49-50-Engineered Blood and Muscle CD133+ Stem Cells Yield Human Dys3+ Myofibers within Injected
Dystrophic Muscles 21 and 45 Days after Intramuscular and Intra-Arterial Transplantation of scid/mdxMice
I.M. I.A.
Tibialis Anterior Tibialis Anterior Quadriceps Soleus
21 days 45 days 21 days
Blood
CD133+
Muscle
CD133+
Blood
CD133+
Muscle
CD133+
Muscle
CD133+
No. 1 Lam A/C+ cells 37 ± 11 41 ± 24 15 ± 8 13 ± 5 22 ± 14 51 ± 21* 20 ± 13
No. 1 Dys3+ fibers 52 ± 23 102 ± 21* 127 ± 63 351 ± 43* 79 ± 24* 33 ± 27 19 ± 6
No. 1 Dys3/Lam A/C+ fibers 31 ± 9 72 ± 17* 83 ± 39 273 ± 69* 35 ± 20 22 ± 14 6 ± 2
No. 2 Lam A/C+ cells 40 ± 22 35 ± 11 8 ± 5 25 ± 6 30 ± 11 82 ± 21* 46 ± 11
No. 2 Dys3+ fibers 38 ± 12 98 ± 37* 132 ± 55 402 ± 38* 74 ± 8* 46 ± 11 25 ± 17
No. 2 Dys3/Lam A/C+ fibers 15 ± 3 64 ± 29* 87 ± 41 282 ± 64* 24 ± 9 34 ± 13 15 ± 10
No. 3 Lam A/C+ cells 33 ± 10 43 ± 8 7 ± 3 14 ± 4 30 ± 17 55 ± 29 33 ± 13
No. 3 Dys3+ fibers 71 ± 42 75 ± 12 106 ± 65 416 ± 67* 57 ± 18* 42 ± 29 11 ± 5
No. 3 Dys3/Lam A/C+ fibers 19 ± 4 44 ± 17* 73 ± 26 303 ± 34* 26 ± 7 23 ± 16 4 ± 1
No. 4 Lam A/C+ cells 39 ± 15 40 ± 19 5 ± 1 21 ± 5* 29 ± 9 68 ± 5* 32 ± 14
No. 4 Dys3+ fibers 80 ± 63 114 ± 48* 173 ± 61 452 ± 58* 90 ± 31 75 ± 39 17 ± 6
No. 4 Dys3/Lam A/C+ fibers 37 ± 17 68 ± 16* 103 ± 33 303 ± 69* 45 ± 20 37 ± 11 13 ± 5
No. 5 Lam A/C+ cells 42 ± 17 52 ± 18 13 ± 7 19 ± 5 43 ± 18 67 ± 26 35 ± 8
No. 5 Dys3+ fibers 61 ± 23 82 ± 41 134 ± 52 317 ± 52* 70 ± 31* 28 ± 12 24 ± 7
No. 5 Dys3/Lam A/C+ fibers 31 ± 8 32 ± 8 71 ± 25 215 ± 18* 43 ± 16 9 ± 3 11 ± 6
No. 6 Lam A/C+ cells 48 ± 27 37 ± 16 17 ± 8 11 ± 6 15 ± 4 66 ± 17* 35 ± 3
No. 6 Dys3+ fibers 59 ± 31 71 ± 42 145 ± 25 562 ± 59* 44 ± 24 58 ± 26 24 ± 10
No. 6 Dys3/Lam A/C+ fibers 15 ± 3 64 ± 29* 97 ± 45 325 ± 44* 27 ± 10 19 ± 7 13 ± 7
Results are expressed as number of human lamin A/C positive cells (Lamin A/C+), human dystrophin positive (Dys3+) fibers, human
Dys3/lamin A/C positive (Dys3/LamA/C+) cells per section of tibialis anterior muscle tissue (±SD) in a longitudinal dimension of
about 800 mm. after intramuscular injection (I.M.) and per section of tibialis anterior, quadriceps, and soleus muscle tissue (±SD)
after intra-arterial injection (I.A.) *p < 0.01.myogenic differentiation after intravascular injection, we
injected the scid/mdx mice in both femoral arteries with
these cells. Human lamin A/C-positive mononuclear cells
were detected within the quadriceps (QD), extensor longus
digitorum (EDL), and TA muscles of all intra-arterially in-
jected animals. Several areas of the QD, EDL, and TA
muscles expressed human dystrophin (Figure 6). In this
experiment, the number of human dystrophin-positive
myofibers was variable between the different muscles of
the injected legs, and the TA muscles showed the highest
one (Table 1). In all injected muscles, most of the human
dystrophin-positive muscle fibers expressed human lamin
A/C. Moreover, human dystrophin positive fibers coex-
pressed the a- and b-sarcoglycan membrane proteins
(Figure 6). To analyze whether injected transduced DMD
muscle-derived CD133+ cells may revert at least in part
the dystrophic phenotype, we performed morphometric
analysis of hematoxylin and eosin-stained muscle
sections from intra-arterially injected scid/mdx mice. The
value of the area of muscle fibers of the QD- and
EDL-injected muscles (1600–1750 mm) was similar to that
observed in uninjected QD and EDL muscles (1550–652 Cell Stem Cell 1, 646–657, December 2007 ª2007 Elsevier1700 mm). However, the value of the area of muscle fibers
of the TA injected with the transduced DMD muscle-
derived CD133+ cells was comprised between 1700 and
1900 mm. The variance coefficient of muscle fibers area
was between 60 and 70 in TA injected, whereas it was be-
tween 40–65 and 30–50 in QD and EDL, respectively. All
these data demonstrate the ability of transduced DMD
muscle-derived CD133+ cells to restore dystrophin ex-
pression and reduce the muscle damage in the dystrophic
mouse muscles following intra-arterial transplantation.
To assess whether the expression of dystrophin and the
improvement in the signs of muscular dystrophy indicated
by morphometric analysis produced sustained recovery
of muscle function, we evaluated the endurance capacity
of injected mice and studied the physiology of injected
limb muscles. Muscle function was evaluated in vitro by
measuring tetanic force of isolated injected TA and EDL
muscles and in vivo by using treadmill exhaustion tests.
In scid/mdx mice, a significant loss in normalized tetanic
force was observed in both muscles in comparison with
WT (Figures 6B and 6C). In TA, the change in tetanic force
appeared significantly counteracted by intra-arterialInc.
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Dystrophin Restoration by Exon-Skipped Stem CellsFigure 5. Expression of Human Dystrophin and Sarcoglycan Proteins in scid/mdx Mice after Intramuscular Transplantation of
Transduced Blood and Muscle-Derived DMD Stem Cells
Intramuscular injection of blood (B, D, F, B0, D0, F0, B00, D00, and F00)- and muscle (A, C, E, A0, C0, E0, A00, C00, and E00)-derived D49-50 DMD CD133+ cells
previously transduced with U7exon51-lentiviral vectors were analyzed for the expression of several human sarcolemmal proteins. Low magnification
of Tibialis Anterior from treated scid/mdx mice reveals extensive reconstitution of the dystrophin complex after double staining with antibodies to
laminin (red, [A0]–[F0]) or a-sarcoglycan (green, [A] and [B]), b-sarcoglycan (green, [C] and [D]), and human dystrophin (Dys3) (green, [E] and [F]).
The right panels (A00–F00) show a merge of the immunostains.injection of transduced DMD muscle CD133+ cells,
whereas no statistical change was observed in EDL
(Figure 6B). Intra-arterial injection was also associated
with an overall amelioration of the endurance capacity of
the mice which showed intermediate time to exhaustion
between WT and untreated littermates (Figure 6D).Cell SDISCUSSION
In this work, we isolated DMD CD133+ cells and charac-
terized their ability to express an exon-skipped version
of human dystrophin after transduction with a lentivirus
carrying a construct designed to skip exon 51 (GoyenvalleFigure 6. Expression of Human Dystro-
phin andAssessment ofMuscle Function
in scid/mdxMice Treatedwith Intra-Arte-
rial Delivery of Transduced Muscle-
Derived DMD CD133+ Cells
Immunofluorescence analysis of intra-arterial
transplanted murine dystrophic TA muscles
(A). Twenty-one days after intra-arterial trans-
plantation, staining with anti-a-sarcoglycan
(green), b-sarcoglycan (green), human dystro-
phin (Dys3; in green), and anti-laminin (in red)
confirmed the presence of several human dys-
trophin+ myofibers. The merge for each cos-
taining is shown in the third column in (A). Nor-
malized tetanic force expressed in kN/m2of (B)
isolated tibialis (black stars, significantly differ-
ent from WT [C57BL6] and scid/mdx, p < 0.05);
(C) isolated EDL (black circles, significantly dif-
ferent from controls, p < 0.05); (D) time to reach
exhaustion in treadmill tests (black check-
marks, significantly different from the other
groups, p < 0.05).tem Cell 1, 646–657, December 2007 ª2007 Elsevier Inc. 653
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Dystrophin Restoration by Exon-Skipped Stem Cellset al., 2004; Denti et al., 2006). We also examined their
ability to participate in muscle regeneration on in vivo
transplantation into scid/mdx mice model. Two distinct
CD133+ cell populations were used, one from blood and
one from skeletal muscle. The myogenic potential of the
blood-derived CD133+ cells was demonstrated in our pre-
vious work (Torrente et al., 2004). Here, we show that the
muscle-derived CD133+ stem cells also have the potential
to differentiate toward both the muscle lineage and the en-
dothelium lineage. Thus, we could compare the in vivo
muscle differentiation of these two transplanted stem
cell populations. The D49-50 DMD deletion was chosen
to test the capacity of the exon-skipping strategy to
restore open reading frame to the dystrophin mRNA
sequence in CD133+ stem cells. Theoretically skipping
exon 51 in this context should eliminate the original frame-
shift, revealing a correct reading frame between exon 48
and exon 52. Targeted U7-based expression plasmids
based on ESE antisense oligonucleotides sequences,
previously observed to skip exon 51 efficiently (Van Deu-
tekom and van Ommen, 2003), were packaged in lentiviral
vectors. In vitro transductions permitted testing of the
capacity of our lentivirus vectors to efficiently deliver the
cassette and to skip the exon 51 in D49-50 DMD-cultured
cells. The skipped blood- and muscle-derived D49-50
stem cells were also able to fuse in vivo with regenerative
fibers and not only express a functional human dystrophin
but also restructure the dystrophin-associated protein
complex as shown by plasmalemmal reexpression of
a and b-sarcoglycans proteins. In this study, genetically
engineered DMD muscle-derived CD133+ cells showed
a better muscle regeneration in terms of spreading and
numbers of positive fibers in comparison with the results
obtained with blood-derived stem cells. Although the
number of human lamin A/C-positive cells decrease
between 21 and 45 days after intramuscular injection of
transduced, blood- or muscle-derived CD133-positive
cells, this was accompanied by a large increase in the
expression of human dystrophin, suggesting that these
genetically engineered cells, after fusion with host regen-
erating myofibers, may protect them against further cycles
of degeneration and regeneration. Our results show too
that human genetically engineered DMD blood- and mus-
cle-derived CD133+ can become located beneath the
basal lamina and distributed along freshly isolated fibers
where they express M-Cadherin, all indicating that they
can differentiate into satellite cells within the recipient
dystrophic skeletal muscle. Further evidence that geneti-
cally engineered human DMD muscle- or blood-derived
CD133-positive cells participate actively to muscle regen-
eration and contribute replenish the pool of satellite cells is
the finding by RT-PCR in injected muscles of scid/mdx,
of expression of human Myf5, Pax7, and M-cadherin.
Together, these data provide strong evidence of the
in vivo myogenic differentiation of the engineered D49-50
blood- and muscle-derived CD133+ stem cells and of
their ability to participate in muscle regeneration in DMD
muscles. However, intramuscular transplantations lead
only to local and focused regeneration, whereas DMD pa-654 Cell Stem Cell 1, 646–657, December 2007 ª2007 Elseviethology affects the whole body musculature. Its effective
treatment requires methods to distribute the injected cells
to these dispersed sites. To circumvent this problem, we
performed intra-arterial injections of transduced DMD
muscle CD133+ stem cells into dystrophic individuals.
We selected the engineered D49-50 muscle-derived
CD133+ stem in relation to their robust myogenic capac-
ity. The data on the recovery of muscle force and endur-
ance after the intra-arterial transplantation of these cells
strongly suggest that cell spreading by this approach
ameliorates morphology and can significantly restore
skeletal muscle function toward normal. Our approach of
using exon-skipping for the expression of human dystro-
phin within the DMD CD133+ cells should allow the use
of the patient’s own stem cells, thus minimizing the risk
of immunological graft rejection (Rivie`re et al., 2006). Nev-
ertheless, for clinical application, the combination of gene
and stem cell therapy approaches does raise some prob-
lems, specifically in terms of biosafety. Principal among
these is the use of lentivirus vectors as shuttles to correct
the genetic defect into DMD stem cells prior to in vivo
transplantation. Hazardous integration of the provirus
can theoretically disturb the control of some housekeep-
ing genes or tumor suppressor genes, and for clinical pur-
poses, this risk, for instance, of developing a tumor after
in vivo injection has to be carefully addressed. The perfor-
mance of additional research focused on exon skipping
will substantially enhance our understanding of the mech-
anisms underlying this effect and may, thus, lead to the
improvement of gene and cell therapy strategies for the
treatment of Duchenne Muscular Dystrophy.
EXPERIMENTAL PROCEDURES
The U7exon51 Lentiviral Vector Construction
and Production
The U7exon51 construct was engineered from the previously de-
scribed U7smOPT-SD23/BP22 (Goyenvalle et al., 2004). Antisense
sequences targeting the mouse exon 23 were replaced by antisense
sequences targeting potential human exon 51 internal splicing en-
hancer (ESE) as previously described (Aartsma-Rus et al., 2002):
h51AON1, 50-TCAAGGAAGATGGCATTTCT-30 and h51AON2, 50-
CCTCTGTGATTTTATAACTTGAT-30 (Figure 3). The resulting U7smOPT-
exon51-AON1/2 fragment was then introduced in a lentiviral vector
construct. All the lentiviral vectors were based on the pRRL-cPPT-
hPGK-eGFP-WPRE constructs (VandenDriessche et al., 2002). To en-
large the vector tropism, lentiviral vectors were pseudotyped with the
VSV-G virus and generated by transfection into 293T cells of the plas-
mid pCMVDR8.74, as previously described (Zufferey et al., 1997). The
infectious particles titer (ip/ml) was determined by quantitative real-
time PCR genomic DNA of transduced cells as described elsewhere
(Charrier et al., 2005).
Lentiviral Vector Transduction
107 to 108 ip/ml were used to transduce blood- and muscle-derived
CD133+ cells. 2 3 104 to 4 3 104 cells were plated per well in 96
wells tissue culture dishes. Vector transduction was transferred in
100 ml of DMEM supplemented with 10% FCS. Four hours posttrans-
duction, the medium was diluted by adding 200 ml per well of previ-
ous medium. The dishes were incubated for 24 hr at 37C and 5%
CO2 before washing and in vivo transplantation or in vitro studies
(cocultures, molecular analysis).r Inc.
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Blood CD133+ cells were collected from peripheral blood of normal or
DMD patients and muscle CD133+ cells were collected from skeletal
muscle biopsies of normal or DMD patients, after informed consent
was obtained, according to the guidelines of the Committee on the
Use of Human Subjects in Research of the Policlinico Hospital of Milan
(Milan, Italy). The protocol of cell isolation was previously described
(Torrente et al., 2004), while primary human muscle cells were obtained
by enzymatic dissociation of biceps brachii muscle biopsies. Mono-
nuclear cells from muscle were then processed through the MACS
magnetic separation column (Miltenyi Biotech). After determination
of the purity of the CD133+ cells, we plated the cells in the presence
of a proliferation medium (PM) composed of DMEM/F-12 (1:1); 20%
FBS, including HEPES buffer (5 mM), glucose (0.6%), sodium
bicarbonate (3 mM), and glutamine (2 mM); SCF (100 ng/ml; TEBU,
Frankfurt, Germany); VEGF (50 ng/ml; TEBU); and LIF (20 ng/ml;
R&D Systems, Inc). The purity of muscle CD133-selected cells was
determined for each isolation experiment. Cell viability was performed
using 7-Amino-actinomycin D (7-AAD) viability probe. For four-color
flow cytometric analysis, at least 10 3 104 to 20 3 104 cells from dis-
sociated muscles or 30 3 104 to 80 3 104 cells from peripheral blood
were incubated with the following monoclonal antibodies (MoAbs):
anti-CD133/2-phycoerythrin (PE) (Miltenyi, Biotec), anti-CD34-
Allophycocyanin (APC) (Becton Dickinson, BD, California, USA), anti-
CDw90 (Thy-1)-fluorescein-isothiocyanate (FITC, BD), anti-VEGF-R2
(KDR)-PE (R&D Systems, Inc.), anti-CD184 (CXCR4, fusin)-
PE-Cy5 (BD), anti-CD45-FITC (BD), and anti-CD20-FITC (BD). For
each MoAb, an appropriate isotype-matched mouse immunoglobulin
was used as a control. After staining performed at 4C for 20 min,
cell suspensions were washed in PBS containing 1% heat inactivated
FCS and 0.1% sodiumazide. Cells were analyzed using a FACSCalibur
flow cytometer and PAINT-a Gate software (BD).
In Vitro Immunohistochemistry and PCR Analysis of Human
Normal and DMD Muscle-Derived CD133+ Cells
For immunocytochemistry, cells plated on lab-tek chamber slides (Life
Technologies) were fixed in 70% ethanol in PBS for 1 min and permea-
bilized for 5 min with 0.5% Triton X-100 in PBS. Cells were than incu-
bated with primary antibodies against the CD31 (1:100; Santa Cruz),
VE-Cad (1:100; Chemicon International, California, USA), CD34
(1:50; BD), VEGF/R2 (1:20; Sigma), anti-a smooth muscle actin
(DAKO, California, USA) CD45 (1:100; BD), CD14 (1:50; Dako),
CD11b (1:200; Dako), desmin (1:20; Sigma), human MyoD (1:50; BD
Biosciences PharMingen), M-cadherin (Goat anti mouse; 1:50; Santa
Cruz), fibronectin (1:150; Sigma), cytokeratin (1:150; Dako), vimentin
(1:200; Santa Cruz), CD4 and CD8 (1:100; Santa Cruz), and CD14
(1:50, Santa Cruz) overnight at 4C. After washing with PBS, cells
were incubated with FITC-conjugated goat anti-mouse IgG for 1 hr
at room temperature (RT) and examined by epifluorescence micros-
copy. Western blot conditions were performed as previously de-
scribed (Torrente et al., 2004). Total RNA was extracted from cells
by TrizolReagent (Invitrogen). First-strand cDNA was prepared by us-
ing Super Script First Strand Synthesis System for RT-PCR (Invitrogen,
Life Technologies), starting from 2 mg total RNA with oligo(dT)12-18
primers. For direct amplification of human markers, primers were spe-
cifically designed in nonhomology region of human-mouse mRNA se-
quences as previously described (Torrente et al., 2004). PCR was per-
formed under the following conditions: 94 for 5 min, then 35 cycles at
94 for 40 s, 68 for 40 s, and 72 for 1 min. Human muscle-derived
CD133+ cells were analyzed for their release of angiogenic factors
on Angiokit (TCS CellWorks Ltd., Buckingham, UK). Briefly, the 3-
day-old medium from human muscle-derived CD133+ cells was
added at various dilutions (1:1, 1:2, and 1:3) to the seeded human en-
dothelial cells (HUVEC) in a 24-well plate. Control wells that received
no conditioned medium were cultured in the presence of VEGF
(2 ug/ml) and Suramin (2 mM). Cultures were monitored daily for the tu-
bule formation and fixed for immunohistochemistry analysis after 12
days of culture. Staining procedure for the expression of CD31 wasCell Sperformed as previously described (Bello et al., 2004). After the immu-
nostaining, the degree of angiogenesis was assessed using the TCS
‘‘AngioSys’’ software package (TCS CellWorks, Cat No. ZHA-1800).
We analyzed the total pixel numbers in six independent microscopic
fields (403). All data are expressed as a percentage of the control wells
cultured in the presence of VEGF and Suramin (referred as 100%) and
expressed as the mean + standard deviation (+ SD) values.
Nested and Classical RT-PCR and DNA Sequencing for the
Evaluation of the Skipping
To verify the in vivo skipping of the exon 51, a series of sixty 10-mm
transverse cryosections obtained over the injected muscle length
were collected in 1.5 ml Eppendorf tubes and mixed with 800 ml of TRI-
zol-reagent (Life Technology). cDNA was obtained as described
above. To detect human dystrophin mRNA, nested RT-PCR was car-
ried out with 1 mg of cDNA using, for the first amplification, a final mix
(Invitrogen) constituted of 13 Taq buffer, 1.5 mM MgCl2, 0.2 mM dNTP
mix, 2.5 units of the Platinium Taq DNA polymerase, 0.2 mM of forward
primer Hex46F (50-AGGAAGCAGATACATTGCT-30), and 0.2 mM of re-
verse primer Hex56R (50-TGAGAGACTTTTTCCGAAGT-30). Thirty-eight
cycles of amplification were used for this first PCR reaction (94C/2
min, 92C/1 min, 52.8C/2 min, and 72C/2 min). PCR products
were purified using the Jetquick PCR product purification spin kit
(Genomed), and a second round of amplification, using 5 ml of purified
PCR, was performed in the same conditions excepted for the MgCl2
(used at 1.5 mM), and for the choice of the primers, Skip47F for the for-
ward (50-GCTTGTAAGTGCTCCCATAAGC-30) and Skip53R for the re-
verse (50-CAGCTTCTTCCTTAGCTTCCAGC-30). The PCR products
were analyzed on 2% agarose gels, and specific bands were purified
for sequence analysis. Classical RT-PCR was also performed to ana-
lyze expression of myogenic markers as previously described (Tor-
rente et al., 2004). To investigate the expression of the most common
dystrophin isoforms, we designed five different pairs of human-
specific primers: dys-427 kD F(50-CCTACAGGACTCAGATCTGG-30)
and R(50-GTCCTCTACTTCTTCCCACC-30 ); dys-260 kD F(50-GCATC
CAGTCTGCCCAGG-30) and R(50-GAGACAGGACTCTTTGGGCAG-30 );
dys-140 kD F(50-GGATGGCATTGGGCAGCG-30) and R(50-GCTCTTT
TCCAGGTTCAAGTGG-30 ); dys-116 kD F(50-CCTCCAAGGTGAAATT
GAAGC-30) and R(50-CTGGCTTCCAAATGGGACC-30); dys-71 kD
F(50-CCACGAGACTCAAACAACTTGC-30) and R (50-CTTGAGGTTGT
GCTGGTCC-30) (Figure 3E). In transplanted and untransplanted scid/
mdx muscles, the endogenous dystrophin was detected using mouse
specific primers as previously described (Goyenvalle et al., 2004). PCR
was performed on cDNA samples obtained from blood and muscle
CD133+ cells cultured in proliferation and differentiation conditions.
To promote myogenic differentiation of the blood-derived CD133+
cells, we cocultured these cells with murine myoblasts with a ratio of
1/50. The myogenesis of muscle-derived CD133+ cells was promoted
in DMEM supplemented with 5% FCS and 5% horse serum (HS).
Transplantation of the Blood- and Muscle-Derived CD133+
Cells into Immunodeficient scid/mdx Mice
A breeding colony of homozygous scid/mdx mice was previously es-
tablished (Torrente et al., 2004; Farini et al., 2007). Two-month-old
scid/mdx mice were anesthetized with ketamine hydrochloride (80
mg/kg) and xylazine (10 mg/kg). In the first experiments, human
CD133+ cells isolated from the normal and dystrophic human muscle
(23 104 cells in 7 ml of PBS) were injected into the right Tibialis Anterior
(TA) muscle of 12 mice as previously described (Torrente et al., 2004).
21 days later, muscle tissues were removed, frozen in liquid-nitrogen-
cooled isopentane and cut on a cryostat into serial sections. Detection
of transplanted human cells and human myofibers was performed
using the anti-human lamin A/C and human spectrin antibodies as
described below. In the second experiments, 2 3 104 to 4 3 104 of
the genetically engineered human DMD blood and muscle-derived
CD133-positive or CD133-negative cells were injected into the right
TA muscles of 24 scid/mdx mice. In all treated animals, muscle degen-
eration-regeneration was induced 24 hr prior to transplantation by antem Cell 1, 646–657, December 2007 ª2007 Elsevier Inc. 655
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Dystrophin Restoration by Exon-Skipped Stem Cellsintense swimming exercise (Torrente et al., 2001). Three injections per
transplantation were performed over the targeted muscle length. In
a third experiment, transduced DMD muscle CD133+ cells were in-
jected into both the right and left femoral artery (5 3 105cells per leg)
of six scid/mdx mice. At 21 and 45 days after intramuscular and
intra-arterial injections, muscle tissues were removed, frozen in liquid
nitrogen-cooled isopentane, and cryostat-sectioned. Serial sections
of 10 mm thickness were counted at 80 mm intervals and examined
by immunohistochemical analysis and hematoxylin and eosin (H&E)
staining.
Immunohistochemistry Analysis
of Injected Muscles
Series of 10 mm transverse cryosections cut over the scid/mdx injected
muscle length were examined by immunohistochemical and H&E
staining. Detection of human dystrophin was performed with monoclo-
nal antibodies directed against the human specific amino-terminal Dys
fragment (NCL-Dys3, Novocastra Laboratories) as previously de-
scribed (Torrente et al., 2004). Rabbit anti-mouse laminin (Sigma, Saint
Louis, USA) was used at the dilution of 1/100. To improve the cadherin
staining, the anti-M-cadherin (Goat anti-mouse, Santa Cruz; 1:50) was
used with 2 mM -Ca2+. Human donor nuclei were stained with mono-
clonal anti-human nuclear lamin A/C (1:100; Novocastra Laboratories).
Detection of the dystrophin-associated complex proteins used mono-
clonal anti-mouse a and b-sarcoglycans (Novocastra Laboratories)
to a final dilution of 1:100. Detection of the human spectrin was
performed using monoclonal antibody directed against the b-chain
(NCL-SPEC1, Novocastra) to a final dilution of 1:100. The effect of ge-
netically engineered human DMD blood- and muscle-derived CD133+
cells on host dystrophic muscle regeneration was evaluated by calcu-
lating the cross-sectional myofiber area, the variance in myofiber di-
ameter, and the percentage of myofibers with centrally located nuclei
using ImageQuest software (LEICA DMIR2). Images were captured
using the Leica TCS SP2 confocal system.
Mechanics of Isolated Muscles
Tibialis and extensor digitorum longus (EDL) (n = 8 each) were dis-
sected in an oxygenated Krebs solution (95% O2 and 5% CO2) under
a stereomicroscope at RT and analyzed as previously described (Rossi
and Bottinelli, 2001). Briefly, muscles, tied up at the tendons by using
silk threads, were transferred to the organ baths where they were
mounted between the hook of a force transducer (Grass) and the
hook of a movable shaft used to adjust muscle length. The perfusion
bath was filled with Krebs solution bubbled with O2-CO2 mixture and
kept at constant temperature (22C). Stimulation was delivered
through plate platinum electrodes connected to a Grass stimulator.
Tetanic isometric contractions (400 ms; 100Hz, supramaximal ampli-
tude) were studied at Lo (the length at which the maximal isometric
force is observed). Tetanic force was normalized to muscle cross sec-
tional area (CSA) and expressed as kN/m2.
Exercise Tolerance Tests
Exhaustion treadmill was used to evaluate the endurance capacity
of mice. Four mice were placed on the belt of motorized treadmill
(six-lane Exer 3/6 Treadmill, Columbus Instruments, Columbus, OH)
supplied with shocker plates. The treadmill was run at an inclination
of 0 at 5 m/min for 5 min, after which the speed was increased
1 m/min every minute. The test was then stopped when the mouse re-
mained on the shocker plate for 20 s without any attempt to reengage
the treadmill, and the time to exhaustion (expressed in minutes) was
determined.
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